Skip to main content

Advertisement

Log in

Profilo metabolico e rischio cardiovascolare in pazienti sottoposti a terapia ormonale per carcinoma della mammella o della prostata

  • RASSEGNA
  • Published:
L'Endocrinologo Aims and scope

Sommario

Grazie ai progressi dei protocolli di terapia oncologica, ad oggi le percentuali di guarigione dei pazienti affetti da carcinoma mammario e prostatico sono significativamente aumentate. Inoltre, in una percentuale significativa di soggetti che non guariscono in modo completo la malattia può essere controllata anche per molti anni. Le terapie ormonali, ad effetto antiestrogeno o antiandrogeno, rappresentano uno dei cardini dei protocolli terapeutici attualmente impiegati in una gran parte dei pazienti affetti da carcinoma prostatico e mammario. A causa della profonda soppressione dei livelli degli steroidi sessuali, queste terapie possono avere ripercussione negative sul profilo metabolico, e quindi sul rischio cardiovascolare, dei pazienti trattati. Pertanto, la gestione complessiva di questi pazienti non può prescindere dalla valutazione degli aspetti metabolici e dall’avvio di opportune terapie per contenerne il rischio cardiovascolare.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Bibliografia

  1. AIOM-AIRTum (2019) I numeri del cancro in Italia. IX edizione. Intermedia Editore, Brescia

    Google Scholar 

  2. Gernaat SA, Ho PJ, Rijnberg N et al. (2017) Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat 164:537–555

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. McGale P, Darby SC, Hall P et al. (2011) Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 100:167–175

    Article  PubMed  Google Scholar 

  4. Bowles EJ, Wellman R, Feigelson HS et al. (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293–1305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ginzac A, Passildas J, Gadéa E et al. (2019) Treatment-induced cardiotoxicity in breast cancer: a review of the interest of practicing a physical activity. Oncology 96(5):223–234

    Article  CAS  PubMed  Google Scholar 

  6. Cheng YJ, Nie XY, Ji CC et al. (2017) Long term cardiovascular risk after radiotherapy in women with breast cancer. J Am Heart Assoc 6:e005633

    PubMed  PubMed Central  Google Scholar 

  7. Sardar P, Kundu A, Chatterjee S et al. (2017) Long-term cardiovascular mortality after radiotherapy for breast cancer: a systematic review and meta-analysis. Clin Cardiol 40:73–81

    Article  PubMed  Google Scholar 

  8. Darby SC, Ewertz M, McGale P et al. (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998

    Article  CAS  PubMed  Google Scholar 

  9. AIOM (Associazione Italiana di Oncologia Medica) (2019) Linee guida neoplasie della mammella. https://www.aiom.it/wp-content/uploads/2019/10/2019_LG_AIOM_Mammella.pdf. Accessed 13 January 2020

  10. Baum M, Buzdar A, Cuzick J et al. (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810

    Article  CAS  PubMed  Google Scholar 

  11. Mouridsen H, Keshaviah A, Coates AS et al. (2007) Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1–98 trial. J Clin Oncol 25:5715–5722

    Article  CAS  PubMed  Google Scholar 

  12. Coombes RC, Kilburn LS, Snowdon CF et al. (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570

    Article  CAS  PubMed  Google Scholar 

  13. Wasan KM, Goss PE, Pritchard PH et al. (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707–715

    Article  CAS  PubMed  Google Scholar 

  14. He Y, Zhang J, Shen G et al. (2019) Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis. Pharmacol Toxicol 20(1):62

    Google Scholar 

  15. Aydiner A (2013) Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. Breast 22:121–129

    Article  PubMed  Google Scholar 

  16. van de Velde CJ, Rea D, Seynaeve C et al. (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321–331

    Article  PubMed  Google Scholar 

  17. AIOM (Associazione Italiana di Oncologia Medica) (2019) Linee Guida Carcinoma della Prostata. https://www.aiom.it/linee-guida-aiom-carcinoma-della-prostata-2019/. Accessed 13 January 2020

  18. Levine GN, D’Amico AV, Berger P et al. for the American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121:833–840

    Article  PubMed  PubMed Central  Google Scholar 

  19. O’Farrell S, Garmo H, Holmberg L et al. (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243–1251

    Article  PubMed  Google Scholar 

  20. Zhao J, Zhu S, Sun L et al. (2014) Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS ONE 9(9):e107516

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bolla M, de Reijke TM, Van Tienhoven G et al. for the EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527

    Article  CAS  PubMed  Google Scholar 

  22. Nguyen PL, Je Y, Schutz FA et al. (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21):2359–2366

    Article  CAS  PubMed  Google Scholar 

  23. Gupta D, Lee Chuy K, Yang JC et al. (2018) Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract 14(10):580–587

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nicoletta Fortunati.

Ethics declarations

Conflitto di interesse

Gli autori Nicoletta Fortunati, Francesco Felicetti, Emanuela Arvat e Enrico Brignardello dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da Marco Gallo.

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 33 kB)

(DOC 48 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fortunati, N., Felicetti, F., Arvat, E. et al. Profilo metabolico e rischio cardiovascolare in pazienti sottoposti a terapia ormonale per carcinoma della mammella o della prostata. L'Endocrinologo 21, 252–256 (2020). https://doi.org/10.1007/s40619-020-00766-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-020-00766-4

Parole chiave

Navigation